Carregando...
Direct Ras G12C inhibitors: crossing the rubicon
Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous cl...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Principais autores: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738074/ https://ncbi.nlm.nih.gov/pubmed/31239544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0499-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|